Core Insights - Novo Nordisk's oral semaglutide tablet has established its dominance in the diabetes and obesity market, with weekly prescriptions surpassing 26,000 by January 23, 2026, showcasing strong market momentum [1][2] - The company is refocusing its strategy on core areas of diabetes and obesity, moving away from a previously diversified business model, and anticipates that oral weight loss medications will capture significant market share [2][7] Product Launch and Market Performance - The oral semaglutide, branded as Wegovy Pill, launched in the U.S. on January 5, 2026, quickly became a leading product in the obesity market, with prescriptions increasing from 3,071 in the first four days to over 18,000 by January 16, and further to 26,109 by January 23 [1][2] - The preference for oral medications over injections among chronic disease patients is expected to enhance treatment adherence, which is crucial for achieving therapeutic efficacy [2] Technological Innovation - Novo Nordisk's SNAC technology has successfully addressed the challenges of oral peptide delivery, which has historically been difficult due to the gastrointestinal environment that degrades peptides [4] - SNAC works by creating a temporary non-covalent bond with the peptide, enhancing its lipophilicity and allowing it to penetrate the intestinal barrier, thus entering the bloodstream effectively [4] Clinical Evidence - The PIONEER clinical trial series has provided robust data supporting the efficacy and safety of oral semaglutide, demonstrating superior glycemic control compared to other diabetes medications [5][6] - In head-to-head trials, oral semaglutide showed significant advantages over DPP-4 inhibitors and comparable efficacy to injectable formulations, challenging the traditional belief that oral medications are less effective [6] Market Strategy in China - The oral semaglutide, branded as 诺和忻, was launched in China in January 2025, marking it as the first approved GLP-1 oral medication in the country, which is expected to significantly impact diabetes treatment [7] - The company has secured patent protection for semaglutide, which will provide a competitive edge against domestic generic manufacturers, despite their interest in developing similar products [7] Digital Health Initiatives - Novo Nordisk is collaborating with local Chinese health platforms to enhance diabetes management through a comprehensive digital health strategy, integrating medication with patient services to improve treatment adherence and outcomes [8] Future Outlook - The introduction of oral semaglutide is seen as a pivotal moment in the management of metabolic diseases, with the potential to simplify long-term health management for patients [9]

Core Viewpoint - GLP-1 receptor agonists (GLP-1RA) have gained significant attention due to their broader health benefits beyond diabetes management, including weight loss and metabolic disorder management [6][8]. Group 1: Mechanism and Benefits - GLP-1RA, such as semaglutide and tirzepatide, help regulate blood sugar levels and have a wide distribution of GLP-1 receptors in various organs, enhancing their effectiveness [6][8]. - These medications assist diabetic patients in managing weight, lowering blood pressure, and improving lipid profiles, contributing positively to overall health [8]. Group 2: Oral Administration and Innovation - The development of oral GLP-1RA, particularly semaglutide, faced challenges in preventing degradation by gastric enzymes, which was overcome using the innovative SNAC technology [9]. - SNAC enhances the permeability of semaglutide and protects it from degradation, allowing for effective absorption and rapid entry into the bloodstream [9]. Group 3: Clinical Evidence and Market Impact - Clinical studies have shown that semaglutide can lead to an average weight loss of 12.1% in Chinese adults, significantly outperforming placebo groups [11]. - The approval of semaglutide injection for long-term weight management by the National Medical Products Administration (NMPA) underscores its market value in China [13]. Group 4: Future Guidelines and Recommendations - GLP-1RA's position in treatment guidelines is rising, with recommendations for early use in certain diabetic patients, particularly those with cardiovascular risks [13]. - As an oral formulation, semaglutide is expected to gain further recognition in future guidelines, benefiting Chinese patients with more evidence-based support [14].